Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence
DH Jung, E Tak, S Hwang, GW Song, CS Ahn… - Liver …, 2018 - journals.lww.com
Both sorafenib and mammalian target of rapamycin inhibitor (mTORi) have antitumor effects.
This study aimed to evaluate their antitumor effects in liver transplantation (LT) recipients …
This study aimed to evaluate their antitumor effects in liver transplantation (LT) recipients …
[PDF][PDF] Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation
C Gomez‐Martin, J Bustamante… - Liver …, 2012 - Wiley Online Library
There is currently no consensus on the most suitable treatment for the recurrence of
hepatocellular carcinoma (HCC) after liver transplantation. This open, multicenter …
hepatocellular carcinoma (HCC) after liver transplantation. This open, multicenter …
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation
K Staufer, L Fischer, B Seegers… - Transplant …, 2012 - Wiley Online Library
Treatment options of recurrent hepatocellular carcinoma (HCC) after liver transplantation are
limited and data on systemic compounds for advanced tumor stages in transplant recipients …
limited and data on systemic compounds for advanced tumor stages in transplant recipients …
Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation
F Invernizzi, M Iavarone, C Zavaglia, S Mazza… - …, 2020 - journals.lww.com
Background. Sorafenib (SOR) is currently used for hepatocellular carcinoma (HCC)
recurring after liver transplantation (LT) when HCC is unsuitable for surgical/locoregional …
recurring after liver transplantation (LT) when HCC is unsuitable for surgical/locoregional …
Efficacy of sorafenib for the treatment of post-transplant hepatocellular carcinoma recurrence
Background The role of sorafenib in patients with hepatocellular carcinoma (HCC)
recurrence after liver transplantation (LT) has been rarely studied. The aim of this study was …
recurrence after liver transplantation (LT) has been rarely studied. The aim of this study was …
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis
Background Data on survival and safety of sorafenib for hepatocellular carcinoma
recurrence after liver transplant are still equivocal. Aim We performed a meta-analysis of …
recurrence after liver transplant are still equivocal. Aim We performed a meta-analysis of …
Sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation
LG Feun, D Levi, J Moon, S Nishida, E Island… - Journal of Clinical …, 2009 - ascopubs.org
e15579 Background: Sorafenib has been approved for the treatment of advanced HCC.
However, there is no data on its use for HCC patients (pts) after liver transplantation (OLT) …
However, there is no data on its use for HCC patients (pts) after liver transplantation (OLT) …
mTOR inhibitor therapy: does it prevent HCC recurrence after liver transplantation?
Prevention of hepatocellular carcinoma (HCC) recurrence after liver transplantation is a
clinical priority. The importance of the mammalian target of rapamycin (mTOR) pathway in …
clinical priority. The importance of the mammalian target of rapamycin (mTOR) pathway in …
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study
C Sposito, L Mariani, A Germini, MF Reyes… - Journal of …, 2013 - Elsevier
BACKGROUND & AIMS: The efficacy of sorafenib in the post-liver transplantation (LT)
setting has been scarcely studied. The aim of this study was to evaluate the efficacy of …
setting has been scarcely studied. The aim of this study was to evaluate the efficacy of …
[HTML][HTML] Therapeutic efficacy of sorafenib in patients with hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis
Z Li, J Gao, SM Zheng, Y Wang, X Xiang… - The Turkish Journal …, 2021 - ncbi.nlm.nih.gov
Background: Hepatocellular carcinoma (HCC) recurrence is still threatening patient survival
after liver transplantation (LT). The efficacy and safety of sorafenib in the setting of post-LT …
after liver transplantation (LT). The efficacy and safety of sorafenib in the setting of post-LT …